
Opinion|Videos|February 7, 2025
Outcomes with Faricimab and Choosing Between the New Therapies
Panelists discuss how faricimab’s dual inhibition of Ang-2 provides additional benefits in vascular stability and inflammation reduction beyond VEGF-A suppression alone, potentially leading to improved durability and treatment outcomes in selected patients.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- In clinical trials, faricimab showed noninferior vision outcomes compared to aflibercept 2 mg. What added benefit do you see by targeting Ang-2?
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
FLORetina 2025: Fibrosis, a limiting factor in visual acuity outcomes in neovascular AMD
2
FLORetina 2025: AI at the forefront of ROP care
3
FLORetina 2025: Port delivery system shows reliable 6-month durability and sustained efficacy in neovascular AMD for up to 7 years
4
FLORetina 2025: Weight and PMA play central roles in preterm foveal development
5













































